Page 46 - DIAGEN

Solid Tumor primeFISH Products

SOLIDTUMOR

PANEL

17-014 ROS1 (6q22) Breakapart

The ROSl (ROS proto-oncogene 1, receptor tyrosine kinase) implicated in Glioblastoma and Chol angiocarcinoma.
gene is located at 6q22.1 and encodes a receptor tyrosine Fusions of ROSl activate the pSTAT3, Pl3K/ AKT/ mTOR
kinase. Translocations affecting ROSl have been identified and SHP-2 phosphatase pathways. GOPC-ROSl fusions
in glio blastoma, cholangiocarcinoma, and non-small celi occur asa result of interstitial deletion of approximately
lung cancer (NSCLC). Patients with ROSl rearrangements 240 kb at 6q22.1. ROSl rearrangements are thought to
have been shown to respond to treatment with ALK/MET define a subset of molecular NSCLC with distinct clinical
tyrosine kinase inhibi tors such as Xalkori®(crizotinib). ROSl features similar to that observed in NSCLC patients with
rearrangements with its fusion partner GOPC (containing ALK rearrangements.
the golgi-associated PDZ and helix motif) have alsa been

BREAKAPART

RH28384 SHGC-149552 RH104060 RH68126 NORMAL
5' 3' 3' 5' 3' 5'
Gen Tel
FAM162B ROS1 GOPC
740 kb 369 kb

6q22.1 DELETION

(Not to scale)

www.diagen.com.tr References
Bergethon K, et al. (2012) J Clin Oncol 30: 863-70.
Bos M, et al. (2013) Lung Cancer 81: 142-3.
Lee SE, et al. (2015) Mod Pathol 28: 468-79.
Charest A et al., Genes Chromosomes Cancer 2003;37:58-71
Matsuura et al., Oncol Rep. 2013 Oct;30(4):1675-80
Charest A et al., Genes Chromosomes Cancer 2003;37:58-71

46 PRODUCT CATALOGUE info@diagen.com.tr